Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)

20260 citationsJournal Articlegold Open Access

Authors

Da-Long Yang · Guangxi Medical University

Chuang Qin · Liuzhou General Hospital

Ning Peng · Guangxi Medical University

Shaoping Liu · Guigang City People's Hospital

Ya-Qun Yu · Guilin Medical University

Jun-Liang Nong · Hengshui University

Fan-Jian Zeng ·

Abstract

Neoadjuvant triple therapy offers OS and EFS benefits for patients with resectable intermediate or advanced HCC, but is associated with an increased risk of adverse events and postoperative complications.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Organ Transplantation Techniques and Outcomes Cholangiocarcinoma and Gallbladder Cancer Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Communications Medicine

Volume 6, Issue 1

DOI: 10.1038/s43856-025-01303-w

Field-Weighted Citation Impact: 0.00